Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

In Insider Trading, Purchases by GlaxoSmithKline and Noted Biotech Investor Randal Kirk

By

Purchases at Oragenics, Amicus Therapeutics, Achillion Pharmaceuticals, and Horsehead Holding.

PrintPRINT
Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:
  • Biotech investor Randal Kirk bought 1,242,490 shares of oral heath technologies company Oragenics (NYSEMKT:OGEN) for $3,106,225. Kirk is the Chairman and CEO of synthetic biology company Intrexon (NYSE:XON).
  • The major pharmaceutical company GlaxoSmithKline (NYSE:GSK) bought 1,500,000 shares of biopharmaceutical company Amicus Therapeutics (NASDAQ:FOLD) for $3,000,000. Amicus focuses on the development and commercialization of pharmacological chaperones, which are orally administered, small-molecule drugs used for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.
  • Boston-based investment advisor Ra Capital Management bought 1,110,000 shares of biopharmaceutical company Achillion Pharmaceuticals (NASDAQ:ACHN) for $2,826,275. Achillion focuses on the discovery, development, and commercialization of treatments for infectious diseases.
  • The investment advisor firm Dalal Street LLC bought 147,585 shares of zinc and nickel producer Horsehead Holding Corp. (NASDAQ:ZINC) company stock for $2,065,347.
For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JB*
$3,106,225
2
BO
JB*
$3,000,000
3
BO
B
$2,826,275
4
BO
B
$2,065,347
5
VP
B
$727,812
6
BO
B
$723,774
7
DIR,BO
B
$561,152
8
CB,DIR
JB*
$537,500
9
DIR
B
$503,309
10
DIR
B
$464,000

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
Q
JS*
$42,971,020
2
BO
Q
JS*
$30,172,778
3
BO
JS*
$19,934,100
4
DIR
S
$13,381,330
5
COO,DIR
AS
$13,288,252
6
CEO,DIR
S
$12,712,812
7
BO
S
$10,662,146
8
CEO,PR,CB
S
$5,435,292
9
BO
S
$5,060,225
10
CEO,DIR,BO
S
$3,670,610

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
PrintPRINT

Busy? Subscribe to our free newsletter!

Submit
 

WHAT'S POPULAR IN THE VILLE